Kymera Therapeutics Inc. Common Stock (KYMR)
Stock · NASDAQ · Health Care
$104.71as of 10/16/2026
Price chart
Active signals
KYMR Signal Track Record
How signals performed across all stocks →What KYMR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | +3.1% | 61% | September 18, 2026 |
| Bollinger Band Breakout | 28 | +3.6% | 61% | August 14, 2026 |
| Bollinger Band Breakdown | 22 | +2.0% | 55% | September 25, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -1.6% | 40% | June 2, 2026 |
| Any 20-session window (baseline) | +0.2% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About KYMR
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, an…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 273
- Website
- www.kymeratx.com/
Fundamentals
- 1-day range
- $104.63$110.68
- Market cap
- $8.75B
- P/E (trailing)
- —
- P/E (forward)
- -21.21
- EPS (trailing)
- $-3.24
- Dividend yield
- —
- Beta
- 2.05
- Avg. volume
- 726.6K
How Kymera Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
23 analyst ratings
Kymera Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- KYMRKymera Therapeutics Inc. Common Stock$104.78▼ 3.11%Market cap $8.75BP/E —$55.26$130.05
- QGENQiagen N.V. Common Shares$46.13▼ 0.09%Market cap $8.60BP/E 22.92$32.53$57.82
- RGENRepligen Corporation Common Stock$175.42▼ 4.75%Market cap $9.00BP/E 244.54$100.99$198.87
- PCVXVaxcyte Inc. Common Stock$63.62▼ 2.53%Market cap $8.50BP/E —$39.87$90.75
- IMVTImmunovant Inc. Common Stock$26.73▼ 2.84%Market cap $8.20BP/E —$16.6$45.42
- KRYSKrystal Biotech Inc. Common Stock$316.58▼ 4.07%Market cap $9.55BP/E 40.85$181.44$382.54
- IBRXImmunityBio Inc. Common Stock$9.18▼ 8.20%Market cap $7.76BP/E —$1.95$12.43
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KYMR Kymera Therapeutics Inc. Common Stock | $8.75B | — | $104.78 | ▼ 3.11% | $55.26$130.05 |
| QGEN Qiagen N.V. Common Shares | $8.60B | 22.92 | $46.13 | ▼ 0.09% | $32.53$57.82 |
| RGEN Repligen Corporation Common Stock | $9.00B | 244.54 | $175.42 | ▼ 4.75% | $100.99$198.87 |
| PCVX Vaxcyte Inc. Common Stock | $8.50B | — | $63.62 | ▼ 2.53% | $39.87$90.75 |
| IMVT Immunovant Inc. Common Stock | $8.20B | — | $26.73 | ▼ 2.84% | $16.6$45.42 |
| KRYS Krystal Biotech Inc. Common Stock | $9.55B | 40.85 | $316.58 | ▼ 4.07% | $181.44$382.54 |
| IBRX ImmunityBio Inc. Common Stock | $7.76B | — | $9.18 | ▼ 8.20% | $1.95$12.43 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- This American Express Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Fridaybenzinga · 10/9/2026
- Kymera: Over-Hyped, Or Developing Next Dupixent? We'll Find Out Very SoonSeekingAlpha · 10/9/2026
- This American Express Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga · 10/9/2026
- Raymond James Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $140Benzinga · 10/9/2026
- Citigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $150Benzinga · 10/5/2026
- Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152Benzinga · 9/22/2026
- Tracking Baker Brothers' Portfolio: Q2 2026 UpdateSeekingAlpha · 9/16/2026
- Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/15/2026
- B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144Benzinga · 9/14/2026
Insider Activity
Insider Actions →- Nello Mainolfi · October 1, 2026 · Option Exercise30.0K @ $2.08
- Nello Mainolfi · October 1, 2026 · Sale262 @ $116.12
- Nello Mainolfi · October 1, 2026 · Sale8.2K @ $115.4
- Nello Mainolfi · October 1, 2026 · Sale7.6K @ $114.43
- Nello Mainolfi · October 1, 2026 · Sale4.9K @ $113.24
- Nello Mainolfi · October 1, 2026 · Sale5.5K @ $112.42
- Nello Mainolfi · October 1, 2026 · Sale3.5K @ $111.44
- Adams Brian · September 4, 2026 · Sale2.1K @ $117.57
- Adams Brian · September 4, 2026 · Sale3.0K @ $116.81
- Adams Brian · September 4, 2026 · Sale1.2K @ $115.55
- Terence Rooney · July 27, 2026 · Grant76.0K
- Terence Rooney · July 27, 2026 · Grant38.0K
- Nello Mainolfi · July 7, 2026 · Option Exercise50.0K @ $2.08
- Nello Mainolfi · July 7, 2026 · Option Exercise4.4K
- Nello Mainolfi · July 7, 2026 · Option Exercise45.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 92.98M
- Total value held
- $6.77B
- Institutional holders
- 251
- Unknown11.70M
- Unknown8.66M
- Unknown7.47M
- Unknown6.06M
- Unknown5.50M
- Unknown5.46M
- Unknown5.06M
- Unknown4.58M
- Unknown3.89M
- Unknown3.19M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Raymond James initiates coverage on Kymera with Outperform rating
Raymond James has started covering Kymera Therapeutics, assigning an Outperform rating and a price target of $140. This new analyst note adds to the current consensus, which has an average target of $139.35 from 23 analysts. Recent discussions also question whether the company's pipeline is over-hyped or developing into a major therapeutic success.
Raymond James initiates coverage on Kymera with Outperform rating. Raymond James has started covering Kymera Therapeutics, assigning an Outperform rating and a price target of $140. This new analyst note adds to the current consensus, which has an average target of $139.35 from 23 analysts. Recent discussions also question whether the company's pipeline is over-hyped or developing into a major therapeutic success.